Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

Biohaven (NYSE:BHVN – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($1.56) ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased federal oversight.

RBC Capital analyst Leonid Timashev maintained a Buy rating on Cytokinetics (CYTK – Research Report) yesterday and set a price target of ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in ...

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

Dr. Se-Jin Lee's discovery of myostatin is not only leading to treatment for spinal muscular atrophy but also fueling the ...

Amy Candido joins Simpson Thacher after more than three years as a partner at Wilson Sonsini Goodrich & Rosati.

Early-phase clinical trials, including phase 1 and some phase 2a studies, serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market.

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

After hours: February 24 at 5:57:57 p.m. EST ...